Detection assays for coronavirus neutralizing antibodies
AssigneesRegeneron Pharmaceuticals, Inc., Vyriad, Inc.
InventorsStephen J. Russell, Kah Whye Peng, Patrycja Lech, Rianna Vandergaast, Timothy Carey
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike(S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.
Claims24
A replication competent recombinant rhabdovirus particle, wherein (i) the rhabdovirus glycoprotein (G) is replaced by a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein or a fragment of the SARS-CoV-2 S glycoprotein comprising the receptor binding domain thereof, and wherein (ii) the rhabdovirus particle comprises a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter protein, wherein the nucleic acid sequence encoding the reporter protein is inserted between a nucleic acid sequence encoding the SARS-CoV-2 S glycoprotein or said fragment of the SARS-CoV-2 S glycoprotein, and a nucleic acid sequence encoding rhabdovirus large (L) protein.
Dependencies are inferred from the claim text.